

Panel on Health Services**List of follow-up actions**

(Position as at 17 July 2004)

Subject	Date of meeting	Follow-up action required	Administration's response
1. Reform of the Medical Council of Hong Kong	4 February 2002	The Administration agreed to give a response on whether it would set up a Complaints Office in the Department of Health (DH) to receive medical complaints, conduct preliminary investigation, make referrals and conduct mediation; and to examine at an appropriate time on gradually moving such Office towards independence.	Letters were issued on 26 April, 30 May, 26 June, 19 September, 29 October, 27 November, 23 December 2002, 30 January, 28 February, 3 and 30 April, 29 May, 25 June, 2 October, 3 and 29 November, 24 December 2003, 3 February, 2 March, 6 April, 11 May, 7 June and 13 July 2004 to remind the Administration to provide a response. To this end, the Administration has repeatedly responded that it will report to members in due course.
2. Working Group on Public/Private Interface - Progress Report	9 December 2002	The Administration undertook to provide statistics on the use of HA private services in the past year, including the number of patients who had used the private services and the types of services they used.	The Administration has advised that liaison with Hospital Authority (HA) is in progress on the requested information.
3. Continue discussion on the commitment for the fight against SARS	5 January 2004	The Administration was requested to provide information on the status of the some 100 doctors recruited during the last SARS outbreak and contract extension, namely, how many of them were still in the employ of HA, had left HA and would not be retained by HA after the expiry of their contract.	The Administration's response is in Appendix I .

Subject	Date of meeting	Follow-up action required	Administration's response
4. 58MM - Construction of a new infectious disease centre attached to Princess Margaret Hospital	8 March 2004	The Administration was requested to provide a paper comparing the expertise and facilities for treating infectious disease patients amongst AHNH, PWH and NDH as well as reason(s) for selecting AHNH over PWH and NDH, for construction of a second infectious centre.	The Administration is reviewing whether the second infectious disease centre should be attached to AHNH and would report to the Panel in due course.
5. Conditions of Tender for pharmaceutical products	19 April 2004	The Administration undertook to provide written response to clarify the conditions of tender for pharmaceutical products, as regards the standards for Market Authorisation and/or product registration.	The Administration's response is in Appendix II .
6. Services and facilities for rehabilitation of discharged mentally ill patients	17 May 2004	The Administration was requested to provide a breakdown of the types of services received by discharged mentally ill patients vis-à-vis the availability of these services, including the average waiting time for these services, from 2000-01 to 2002-03.	The Administration's response already issued vide LC Paper No. CB(2)3099/03-04(01) on 15 July 2004.
7. Studies on health care financing and feasibility of a medical savings scheme in Hong Kong	14 June 2004	The Administration was requested to provide comprehensive data and results of studies of various health care financing options.	The Administration would provide the requested information in due course.

Subject	Date of meeting	Follow-up action required	Administration's response
8. Prince of Wales Hospital - current condition and way forward	14 June 2004	The Administration undertook to provide results of the feasibility study of Public/Private Partnership (PPP) in either refurbishing or redeveloping the PWH.	The Administration would inform members the outcome of the feasibility study when available.

Council Business Division 2
Legislative Council Secretariat
17 July 2004

Our ref: HWF/H/33/83

Tel: (852) 2973 8121

Fax: (852) 2840 0467

17 July 2004

By Fax: 2509 9055

Clerk to Panel on Health Services
Legislative Council
8 Jackson Road
Central, Hong Kong
(Attn: Ms Mary So)

Dear Ms So,

**List of Follow-up Items
Commitment for the Fight against SARS**

I am writing to respond to the query raised by the Hon LAW Chi-kong at the meeting on 5 January 2004 regarding the 110 additional doctors recruited by the Hospital Authority during the SARS outbreak last year. At of today, around half of them are still under the employment of the Hospital Authority.

Yours sincerely,

(Paul Cheng)
for Secretary for Health, Welfare and Food

Our ref:
Your ref:

Tel: (852) 2973 8121
Fax: (852) 2840 0467

17 July 2004

By Fax: 2509 9055

Clerk to Panel on Health Services
Legislative Council
8 Jackson Road
Central, Hong Kong
(Attn: Ms Mary So)

Dear Ms So,

List of Follow-up Items
Tendering System for Pharmaceutical Products

I am writing to respond to the query raised by the Hon TANG Siu-tong at the meeting on 19 April 2004 regarding the procurement of Pharmaceutical products by the Government Logistics Department (GLD) on behalf of the Hospital Authority (HA).

2. Under the Pharmacy and Poisons Regulation (Cap 138A), medicines must be registered with the Pharmacy and Poisons Board before they can be supplied for use in Hong Kong. Registration of the drug in Hong Kong is an essential but not the only requirement for purpose of procuring drugs for use in public hospitals. In respect of off-patent drugs, the HA follows the "Drug Purchasing Guidelines of the Public Health Service of Hong Kong on Multisource (Generic) Pharmaceutical Products" drawn up by the Drug Selection Committee of the Department of Health. The Guidelines stipulate among other things that for pharmaceutical products manufactured outside Hong Kong, the tenderer should be required to produce, apart from the Certificate of Drug/Product Registration issued by the Pharmacy and Poisons Board of Hong Kong, the Marketing Authorisation issued by the national control authority of a member country of the International Conference on

Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, or from the national control authority of the People's Republic of China, Australia or Canada. These guidelines have been built into the terms and conditions of the tender for drug procurement to provide added assurance of the quality, safety and efficacy of the drugs used in public hospitals.

Yours sincerely,

(Paul Cheng)
for Secretary for Health, Welfare and Food